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Background: A randomized and controlled clinical study was performed to evaluate the use of neurofeedback (NF)
to treat attention-deficit/hyperactivity disorder (ADHD) in children and adolescents.
Methods: The ADHD population was selected from an outpatient clinic for Child and Adolescent Mental Health in
Norway. Ninety-one of the 275 children and adolescents ranging in age from 6 to 18 years (10.5 years) participated
in 30 sessions of an intensive NF program. The reinforcement contingency was based on the subjects’ production
of cortical beta1 activity (15–18 Hz). The ADHD participants were randomized into three groups, with 30 in the NF
group, 31 controls in a group that was given methylphenidate, and 30 in a group that received NF and
methylphenidate. ADHD core symptoms were reported by parents using the parent form of the Clinician’s Manual
for Assessment by Russell A. Barkley.
Results: Ninety-one children and adolescents were effectively randomized by age, sex, intelligence and distribution
of ADHD core symptoms. The parents reported significant effects of the treatments, but no significant differences
between the treatment groups were observed.
Conclusions: NF was as effective as methylphenidate at treating the attentional and hyperactivity symptoms of
ADHD, based on parental reports.
Trial registration: Current Controlled Trials NCT01252446
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Attention-deficit/hyperactivity disorder (ADHD) is a de-
velopmental mental disorder characterized by persistent
symptoms of inattention or inattention in combination
with hyperactivity and impulsivity. Its prevalence may be
up to one in four [1,2]. The severity of these symptoms
and its enduring nature are known to impair a person’s
capacity to effectively function. Treatment programs
using behavioral and pharmacotherapeutic approaches
are well established [3,4]. The Multimodal Treatment
study (MTA) of ADHD identified advantages of* Correspondence: nezlad@gmail.com
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reproduction in any medium, provided the ormultimodal treatment [1,5,6]. Because of rapid improve-
ments in attention and reduced hyperactivity, many chil-
dren with ADHD have been treated with stimulants [7-
9]. However, improvements in social and academic skills
following stimulant treatment have not been reported
[9]. In addition, concerns with the benefits and side
effects of long-term stimulant treatment have also been
noted [10,11].
Many clinical trials have found that neurofeedback
(NF) effectively treats the symptoms of ADHD [12,13].
The effects of NF have been described as improved at-
tention, decreased hyperactivity, and increased academic
and social skills [1,14,15]. However, other studies have
only found improvements in attention [16], and two
studies with large sample sizes did not find significant
improvements in core ADHD symptoms [11,17].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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treatment when given alone or in combination with
medications [11]. One study did not find significant
treatment responses between Ritalin and NF [17].
NF is a learning process in which the brain is
rewarded for positive changes in its activity [13]. The re-
sponse to this learning process is visual or auditory feed-
back. In NF, the placement of the electrodes and the
frequency of stimulation are important. The Inter-
national 10-20 system is a recognized method to de-
scribe and apply the location of scalp electrodes in the
context of an electroencephalography (EEG) exam or ex-
periment. Most NF studies have used the standardized
electrode placements Cz, C3, and C4 [14]. Some studies
included frontal electrodes when using NF to treat
ADHD, such as the Fz, F3, and F4 electrodes [14]. Sev-
eral NF protocols for treating ADHD are available.
Single-channel protocols (unipolar) developed by Lubar
and interhemispheric (bipolar) protocols developed by
Othmers are widely practiced and supported by large-
scale clinical studies [18-20].
Different approaches regarding NF treatment have
been developed for ADHD [1,12,21]. The most fre-
quently used frequencies enhance beta (15-18 Hz) and
inhibit theta (4-7 Hz) brain activity [22]. Sensorimotor
rhythm (SMR; 12-15 Hz) protocols that enhance SMR
activity (low beta activity), alpha/theta (8–11 Hz/4–
7 Hz) protocols that enhance alpha brain activity, and
SCP (slow cortical potentials) protocols that reward po-
larity changes in EEGs are also used [23]. Usually no
more than two different treatment protocols are used in
NF treatments [22].
The lack of large and controlled studies may have lim-
ited the use of NF treatments in the clinic [24-27]. Many
prospective controlled studies have used either stimu-
lants or waiting lists as the control groups [17]. Only a
few studies were randomized and controlled trials
[16,17,28-30].
In addition, several non-randomized studies found a
large effect size (ES) for attention and a medium ES for
hyperactivity [31], but a randomized study by Arns and
Linden found a small ES for hyperactivity [14,32].
Use of sham feedback (placebo) for evaluating the effi-
cacy of NF in the ADHD population was declared un-
ethical by the University of California, San Diego
[24,33]. This is the most likely reason why standard
medication treatments have been applied to the control
groups in NF research studies.
The present study was a controlled and randomized
clinical study that included children and adolescents with
ADHD, who were followed at a Child and Adolescent
Mental Health Clinic in Norway. The aim of the study
was to evaluate the effects of NF on the core symptoms of
ADHD, including attention and hyperactivity.Methods
Subjects
Over a period of 3 years (2007-9), 628 children and ado-
lescents aged six through 18 years were referred for the
treatment of ADHD to the Child and Adolescent Mental
Health Clinic, Haugesund Hospital, Rogaland County in
Norway. Of these, 285 (45 %) met the criteria for ADHD
according to the International Classification of Disease
(ICD-10) (Figure 1). All children and adolescents with
ADHD were invited to participate in the study. Ten of
these subjects were excluded because of a low IQ (<70),
and 155 refused to participate. These children were of a
similar gender and age as the participants. After
randomization, 39 children and adolescent dropped out of
the study: 13 randomized to NF group, 15 to medication
group and 11 belonged to combined NF/medication group.
The treatment was completed successfully in 91 (70 %)
children and adolescents (Figure 1).
ADHD
The ADHD-referred population through 1 year (2007)
has been described in detail in earlier papers [34,35].
Children referred for ADHD underwent a clinical assess-
ment. The assessment included a child appropriate med-
ical examination, a clinical psychiatric interview, and
observations to assess ADHD and other appropriate
diagnoses. Questionnaires regarding ADHD were filled
in by the child, or by the parent or teacher of the
child. The medical examination was done to exclude
somatic conditions as the cause of the ADHD symp-
toms. A child psychiatrist evaluated the assessments
and categorized the child as having ADHD or a non-
ADHD condition according to ICD-10 diagnostic
criteria.
Inclusion criteria
All children with ADHD met the following criteria to be
included in the study: 1) symptomatology consistent
with ICD10 criteria for the diagnosis of ADHD; 2) age
6–18 years; 3) cognitive function above IQ 70. The chil-
dren were evaluated using the Wechsler Intelligence
Scale for Children (WISC-IV) [36,37].
Treatment groups
The children with ADHD were randomly placed into
three groups: 1) the NF group received NF; 2) the NF +
MED group received NF and methylphenidate (MPH);
and 3) the MED group received MPH (Figure 1).
NF
NF is designed to change certain types of EEG activity
[38,39]. The goal of the NF treatment was to enhance
beta and depress theta activity [19].
Figure 1 Clinical population of children with ADHD who were invited to participate in this randomized neurofeedback trial.
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back regarding their own brain activity. Unipolar
placed sensors on the scalp measured brain activity,
and a computer processed the signals as brainwave fre-
quencies. The flow of this activity is shown to the sub-
ject, who attempts to change the activity level. Some
frequencies are susceptible to promotion and others
are susceptible to being diminished. Such information
was presented to the children and adolescents in the
form of a video game or film. When the children and
adolescents played the video game or watched the films,
they produced brainwave activity that was "shaped" to-
ward more regulated performance. NF in the study was
conducted using the Infinity software and equipment
supplied by the biofeedback/NF and psycho-physiological
instrument manufacturer Thought Technology [40].
A beta/theta NF treatment protocol for ADHD was
used, including the appropriate frequency ranges for
the EEGs and electrode placements. Beta enhancement
(16–20 HZ) and Theta suppression (4–7 Hz) were
assessed. The treatment site used was in the central
area and unipolar electrodes was placed on the Cz,
whereas the ground electrode was placed on the ear-
lobe [18].
NF was conducted three times a week with 30 treat-
ments for each child and adolescent. Each treatment
lasted 40 minutes and was separated into pre and post
5-minute baseline periods (alpha training) and 30minutes of NF (beta/theta training). Theta activity was
defined as 4–7 Hz, alpha activity as 8–12 Hz, SMR
activity as 13–15 Hz, beta activity as 16–20 Hz, and
electromyography (EMG) activity as 80–150 Hz activity
[41]. The events above these threshold levels were moni-
tored. The standards used in the treatment were to de-
crease theta activity by inhibiting high amplitude theta
activity or by rewarding high amplitude beta activity. The
treatment effect was defined as increased beta/SMR ac-
tivity of 13–20 Hz, decreased theta activity of 4–7 Hz,
and decreased EMG activity.
Subjects in the MED and NF/MED group were admi-
nistered methylphenidate (MPH) twice per day at the
recommended dose 1 mg per kg with the final medica-
tion doses from 20 to 60 mg daily doses.
Pre- and post-evaluation
Two core symptoms of ADHD were evaluated. Attention
and hyperactivity were evaluated using the Clinician’s
Manual for the Assessment of Disruptive Behavior Disor-
ders – Rating Scale for Parents, from Russell A. Barkley
[42]. The manual offers an effective tool for assessing at-
tention and hyperactivity. The scale is divided into sub-
scales for inattention and hyperactivity, and a total score.
Normative data are rated according to the age (5–18 years)
and gender of the subject. The children were evaluated in
two different periods during the study (T1, T2). The base-
line evaluation T1 was completed prior to the treatment.
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in ADHD core symptoms from T1 to T2. All children
underwent post-treatment evaluations approximately
1 week after the NF had been completed (T2).
The Regional Ethics Committee on Medical Research
approved the project protocol used in this study, and
written consent was obtained from all subjects and their
parents.
Statistical Analysis
Basic descriptive methods (descriptive, Analyses of Vari-
ance (ANOVA), exact χ2 test) were used to investigate
the baseline data. The treatment effects were investi-
gated using a general linear model (GLM) for repeated
measures, which was implemented for each of the sub-
scales (total score, inattention, and hyperactivity). The
model included the raw scores at both time points as
dependent variables and the treatment groups as factors.
We fitted both an unadjusted model and a model
adjusted for sex and age. Even if the adjusted model may
be more complete and more reliable, it was reasonable
to examine the unadjusted model because of the small
sample size and concomitant lack of power in the
adjusted model. In the GLM, we estimated both within-
subjects contrasts to test treatment-induced changes in
the ratings and between-groups effects to test for differ-
ences between the treatments. Significant differences
were further examined using post-hoc tests. Addition-
ally, we estimated the standardized ES δRM for each
treatment change [43].
Note that we used a negative definition of the treat-
ment changes (T1-T2) because we wanted an improve-
ment associated with a positive number.
The general significance level was set to 0.05. For the
baseline investigation we had to take into account the
effects of multiple comparisons. Because of the highTable 1 A clinical randomized controlled Neurofeedback stud
Total Medication
Mean (SD) Mean (SD)
Demografics
Children participating1 91 (100 %) 31 (34 %)
Sex (boys)1 72 (80 %) 27 (87 %)
Age 11.2 (2.8) 10.9 (2.4)
IQ 87 (14) 87 (15)
ADHD core symptoms3
Total 34.1 (8.9) 35.8 (10.8)
Attention 16.7 (4.7) 17.4 (5.1)
Hyperactivity 17.3 (5.2) 18.2 (6.2)
1 Number (%).2 ANOVA for the null-hypotheses that the values for the randomized
4 Exact χ2−–test.correlation between a number of the investigated variables
(Barclay ratings), a Bonferroni corrections method would
be too conservative. As such, we decided to set the signifi-
cance level to 0.01, as a compromise between a Bonferroni
correction and not accounting for multiple comparisons.
In the GLM, we investigated only highly correlated vari-
ables, thereby reducing the number of comparisons.
Therefore, we did not adjust the significance level. All
computations were done using PASW 18.
Results
Subjects and randomization
There were no significant differences in demographic
factors or ADHD core symptoms between the treatment
groups at baseline (T1) (Table 1).
Almost one third of the subjects dropped out of the
study (Figure 1). Most of them did not start the treat-
ment because of their parents’ decision (30/39) or be-
cause of the subject’s decision (6). Three children did
not complete the follow-up (T2) questionnaires after the
NF. The 91 subjects who completed the treatment were
similar to the 39 who dropped out of the treatment
regarding their socio-demographic status, in terms of
their family structure, number of siblings, parents’ edu-
cation, economic resources, and other support. There
were no significant differences in their academic skills
(IQ mean difference: -9.8, 95 % CI: (-7.9, 5.9)).
Results within the treatment groups
Parents reported significant changes in all scales with-
in the three treatment groups (unadjusted, p < 0.001,
Table 2). The change was quite strong for hyperactivity,
but weak for attention. Consequently, the size of the
change for the total scale was dominated by the hyper-
activity change. After adjusting for age and sex, no sig-
nificant changes were found (adjusted, Table 2).y with 91 participants
Neurofeedback+
Medication Neurofeedback
Mean (SD) Mean (SD) p-value
30 (33 %) 30 (33 %)
23 (77 %) 22 (73 %) 0.514
11.2 (2.8) 11.4 (3.1) 0.772
85 (13) 89 (14) 0.752
33.8 (7.8) 32.6 (7.7) 0.392
17.2 (4.9) 15.5 (4.0) 0.222
16.5 (4.9) 17.1 (4.5) 0.472
groups are equal. 3 Barkley rating scale based on parents score.
Table 2 Parents report of ADHD core symptoms (attention, hyperactivity, total score) regarding the treatments (NF, MED, combined)
Pre treatment Post treatment Pre-Post change (T1-T2)
1 Treatment effect2
Barkley rating scores N Mean 95 % CI N Mean 95 % CI N Mean3 95 % CI Effect size4 p-unadj.5 p-adj.6 p-uadj.5 p-adj.6
Total < .001 0,310 0.173 0,228
Medication 29 34,5 (30.6, 38.5) 22 27,8 (24.0, 31.6) 22 7.9 (4.5, 11.4) 1.79
Neurofeedback +Medication 24 32,6 (28.6, 36.6) 22 23,7 (19.8, 27.6) 22 8,6 (5.0, 12.2) 1.76
Neurofeedback 23 37 (33.9, 40.0) 19 26,7 (23.4, 30.1) 19 10,7 (7.6, 13.8) 2.25
Attention < .001 0,738 0,098 0,139
Medication 29 15,9 (13.8, 18.0) 22 15,2 (13.2, 17.2) 22 1,5 (-0.3, 3.3) 0.70
Neurofeedback +Medication 24 15,9 (13.9, 18.0) 22 14,5 (12.0, 17.2) 22 1,1 (-0.7, 3.0) 0.46
Neurofeedback 23 19,2 (17.2, 21.1) 19 16,6 (14.5, 18.7) 19 3,1 (1.6, 4.5) 2.08
Hyperactivity < .001 0,077 0,101 0,186
Medication 29 18,7 (16.3, 21.0) 22 12,5 (10.2, 14.4) 22 6,5 (4.3, 8.6) 2.45
Neurofeedback +Medication 24 16,7 (14.3, 19.0) 22 9,1 (6.8, 11.4) 22 7,5 (4.9, 10.0) 1,75
Neurofeedback 23 17,8 (15.9, 19.6) 19 10,1 (8.0, 12.2) 19 7,6 (5.6, 9.6) 2.88
1 Tests for within-subject-contrast in the General linear modell (GLM). 2 Between-groups-effect in the GLM. 3 Mean of the differences, i.e. excluding drop outs at one missing point. 4 Effect size measure δRM (ref Morris).
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Based on the parents’ reports, we did not observe signifi-
cant differences between the treatment groups. Neither
the between-groups effects in the GLM nor the post-hoc
tests showed any significant change scores, for any scales
or pair of treatment groups (Table 2). We did not report
the ESs or the results of the post-hoc tests since there
were no significant differences.
Generally, our comparisons of the treatments had low
powers. Although not significant, the NF group showed
more than double the pre–post change in attention
compared with the other two treatments (3.1 vs. 1.1 and
1.5 for the means). Additionally, we noted that the MED
and NF+MED group had a confidence interval that
included 0. The NF group had the largest ES δRM for all
scales, but one should be careful interpreting this obser-
vation since those three scales are highly correlated. For
all scales, we noted that the p-value for the unadjusted
models were lower than for the adjusted models.
Discussion
In the present controlled and randomized clinical trial,
NF treatment seemed to improve the core symptoms of
ADHD, as assessed by parental reports. In addition, NF
and MPH produced similar improvements.
The strength of the present study was the effective
randomization by age, sex, and intelligence, and the dis-
tribution of ADHD core symptoms (hyperactivity and at-
tention). However, the number of subjects in each
treatment group was somewhat low.
NF improved attention and hyperactivity symptoms in
children and adolescents with ADHD. This is in accord-
ance to findings in other studies, including a study by
Kaiser, Thomsen and Othmer that found significant
improvements in ADHD symptoms with NF for more
than three in four ADHD subjects [32,44]. We did not
find significant difference between the three investigated
treatments in the improvement of ADHD core symp-
toms. This is in accordance with the work of Rossiter
and Fuchs, who found in a rather large sample size that
effects of NF on hyperactivity and attention ( ES 1.01-
1.71) are equivalent to those obtained with stimulant
drugs (0.80-1.80) [17,30]. Consequently, NF can be sug-
gested to produce equivalent beneficial effects for
ADHD as medications. Furthermore, our findings sup-
port the suggestion by Fuchs and Lubar to introduce NF
as a treatment option for children with ADHD whose
parents favored a non-pharmacological treatment
[21,30].
However, regarding the improvement of the core
symptoms of ADHD, nonspecific factors may contribute
to the positive effects induced by NF [14,16]. Mainly,
there are three nonspecific factors described in previous
studies that may result in ADHD symptomimprovement. These include the extraordinary amount
of time spent with the therapist during NF, better motiv-
ation for changes in ADHD symptoms, and cognitive-
behavioral training introduced under NF [26,32]. These
factors may explain some improvement of hyperactivity,
but may be a minor factor.
Even if we did not find significant differences in the
core symptoms of ADHD, we observed a lower ES for
the combined treatment for all symptoms. Such a ten-
dency would lie in contrast to previous studies, which
found NF and MPH was associated with the best
improvements in the core symptoms of ADHD [11].
The results of the present study support the use of NF
as an alternative treatment for ADHD, especially in the
20% of children with ADHD who do not respond to
medications. In addition, findings from this study sup-
port previous suggestions that medications may be
reduced when given in combination with other treat-
ments for ADHD [21].
Conclusions
NF produced a significant improvement in the core
symptoms of ADHD, which was equivalent to the effects
produced by MPH, based on parental reports. This sup-
ports the use of NF as an alternative therapy for children
and adolescents with ADHD.
Key messages
1. NF improves the core symptoms of ADHD based on
parental reports.
1. NF and MPH produce equivalent improvements in
the core symptoms of ADHD based on parental reports.
Abbreviations
ADHD: Attention-deficit/hyperactivity disorder; NF: Neurofeedback;
MED: Medication.
Competing interests
The authors declare no potential conflicts of interests with regard to the
authorship or publication of this article.
Authors’ contributions
NSD and IBE made substantial contributions to the design, analysis, and
interpretation of the data, and they were involved in drafting the manuscript
and revising it critically. JA contributed to the statistical analyses and data
interpretation. DG acquired the funding and contributed to the study design.
All authors read and approved the final manuscript.
Acknowledgments
We thank the staff at the Child and Adolescent Psychiatry Department of the
Helse Fonna Hospital of Haugesund for support in completing this study and
collecting the data for this article. We thank the Solveig and Johan P.
Sommers Foundation and National Competency Center for AD/HD in
Norway for financially supporting this project. The project was further
supported by the University of Bergen, Center for Child and Adolescent
Mental Health.
Author details
1Department of Child and Adolescent Psychiatry, Helse Fonna Haugesund
Hospital, Vinjesgate 10, Haugesund 5501, Norway. 2Center for Child and
Adolescent Mental Health, University of Bergen, Bergen, Norway. 3Center for
Duric et al. BMC Psychiatry 2012, 12:107 Page 7 of 8
http://www.biomedcentral.com/1471-244X/12/107Clinical Research, Haukeland University Hospital, Bergen, Norway.
4Department of Research, Helse Fonna Haugesund Hospital, Haugesund,
Norway. 5Department of Child and Adolescent Psychiatry, Haukeland
University Hospital, Haukeland, Norway. 6Department of Clinical Medicine,
University of Bergen, Bergen, Norway.
Received: 29 November 2011 Accepted: 18 July 2012
Published: 10 August 2012References
1. Monastra VJ, Lynn S, Linden M, Lubar JF, Gruzelier J, LaVaque TJ:
Electroencephalographic biofeedback in the treatment of attention-deficit/
hyperactivity disorder. Appl Psychophysiol Biofeedback 2005, 30(2):95–114.
2. Barkley RA: Attention-deficit hyperactivity disorder: A handbood for diagnosis
and treatment (2nd ed.). New York: Guilford Press; 1998.
3. Safren SA, Sprich S, Mimiaga MJ, Surman C, Knouse L, Groves M, Otto MW:
Cognitive behavioral therapy vs relaxation with educational support for
medication-treated adults with ADHD and persistent symptoms: a
randomized controlled trial. JAMA 2010, 304(8):875–880.
4. Zwi M, Jones H, Thorgaard C, York A, Dennis JA: Parent training
interventions for Attention Deficit Hyperactivity Disorder (ADHD) in
children aged 5 to 18 years. Cochrane Database Syst Rev 2011,
12. CD003018.
5. Langberg JM, Arnold LE, Flowers AM, Epstein JN, Altaye M, Hinshaw SP,
Swanson JM, Kotkin R, Simpson S, Molina BS, et al: Parent-reported
homework problems in the MTA study: evidence for sustained
improvement with behavioral treatment. J Clin Child Adolesc Psychol 2010,
39(2):220–233.
6. Reeves G, Anthony B: Multimodal treatments versus pharmacotherapy
alone in children with psychiatric disorders: implications of access,
effectiveness, and contextual treatment. Paediatr Drugs 2009,
11(3):165–169.
7. Barbaresi WJ, Katusic SK, Colligan RC, Pankratz VS, Weaver AL, Weber KJ,
Mrazek DA, Jacobsen SJ: How common is attention-deficit/hyperactivity
disorder? Incidence in a population-based birth cohort in Rochester,
Minn. Arch Pediatr Adolesc Med 2002, 156(3):217–224.
8. Barbaresi W, Katusic S, Colligan R, Weaver A, Pankratz V, Mrazek D, Jacobsen
S: How common is attention-deficit/hyperactivity disorder? Towards
resolution of the controversy: results from a population-based study.
Acta Paediatr Suppl 2004, 93(445):55–59.
9. Wagner KD: Management of treatment refractory attention-deficit/
hyperactivity disorder in children and adolescents. Psychopharmacol Bull
2002, 36(1):130–142.
10. Jensen PS, Arnold LE, Swanson JM, Vitiello B, Abikoff HB, Greenhill LL,
Hechtman L, Hinshaw SP, Pelham WE, Wells KC, et al: 3-year follow-up of
the NIMH MTA study. J Am Acad Child Adolesc Psychiatry 2007,
46(8):989–1002.
11. Monastra VJ, Monastra DM, George S: The effects of stimulant therapy,
EEG biofeedback, and parenting style on the primary symptoms of
attention-deficit/hyperactivity disorder. Appl Psychophysiol Biofeedback
2002, 27(4):231–249.
12. Monastra VJ: EEG and neurofeedback findingsin ADHD:AN empirical
response. The ADHD Report 2004, 12:5–8.
13. Fox DJ, Tharp DF, Fox LC: Neurofeedback: an alternative and efficacious
treatment for Attention Deficit Hyperactivity Disorder. Appl Psychophysiol
Biofeedback 2005, 30(4):365–373.
14. Arns M, de Ridder S, Strehl U, Breteler M, Coenen A: Efficacy of
neurofeedback treatment in ADHD: the effects on inattention,
impulsivity and hyperactivity: a meta-analysis. Clin EEG Neurosci 2009,
40(3):180–189.
15. Lubar JO, Lubar JF: Electroencephalographic biofeedback of SMR and
beta for treatment of attention deficit disorders in a clinical setting.
Biofeedback Self Regul 1984, 9(1):1–23.
16. Bakhshayesh AR, Hansch S, Wyschkon A, Rezai MJ, Esser G: Neurofeedback
in ADHD: a single-blind randomized controlled trial. Eur Child Adolesc
Psychiatry 2011.
17. Rossiter T: The effectiveness of neurofeedback and stimulant drugs in
treating AD/HD: part II. Replication. Appl Psychophysiol Biofeedback 2004,
29(4):233–243.18. Friel PN: EEG biofeedback in the treatment of attention deficit
hyperactivity disorder. Altern Med Rev 2007, 12(2):146–151.
19. Othmer SF: Interhemispheric EEG training. J Neurotherapy 2005, 9:87–96.
20. Lubar J: Quantitative Electroencephalographic Analysis (QEEG) Databases
for Neurotherapy: Description,Validation, and Application. Haworth
Medical Press 2004.
21. Lubar JF, Lubar JO: Neurofeedback Assessment and Treatment for Attention
Deficit/Hyperactivity Disorders Introduction to Quantitative EEG and
Neurofeedback. New York: Academic Press; 1999:103–141.
22. Egner T, Zech TF, Gruzelier JH: The effects of neurofeedback training on
the spectral topography of the electroencephalogram. Clin Neurophysiol
2004, 115(11):2452–2460.
23. Leins U, Hinterberger T, Kaller S, Schober F, Weber C, Strehl U:
Neurofeedback for children with ADHD: a comparison of SCP- and
theta/beta-protocols. Prax Kinderpsychol Kinderpsychiatr 2006,
55(5):384–407.
24. Kaiser DA, Othmer SF: Effect of Neurofeedback on Variables of Attention
in a Large Multi-Center Trial. Journal of Neurotherapy 2000, 4(1):5–15.
25. Barkley AR: Continuing concerns about EEG biofeedback/neurofeedback.
ADHD Report 1993.
26. Loo SK, Barkley RA: Clinical utility of EEG in attention deficit hyperactivity
disorder. Appl Neuropsychol 2005, 12(2):64–76.
27. Stjernholm O: Neurofeedback as ADDH therapy. Ugeskr Laeger 2010,
172(33):2221–2225.
28. Gevensleben H, Holl B, Albrecht B, Vogel C, Schlamp D, Kratz O, Studer P,
Rothenberger A, Moll GH, Heinrich H: Is neurofeedback an efficacious
treatment for ADHD? A randomised controlled clinical trial. J Child
Psychol Psychiatry 2009, 50(7):780–789.
29. Spencer TJ, Biederman J, Wilens TE, Faraone SV: Novel treatments for
attention-deficit/hyperactivity disorder in children. J Clin Psychiatry 2002,
63(Suppl 12):16–22.
30. Fuchs T, Birbaumer N, Lutzenberger W, Gruzelier JH, Kaiser J:
Neurofeedback treatment for attention-deficit/hyperactivity disorder in
children: a comparison with methylphenidate. Appl Psychophysiol
Biofeedback 2003, 28(1):1–12.
31. Kropotov JD, Grin-Yatsenko VA, Ponomarev VA, Chutko LS, Yakovenko EA,
Nikishena IS: ERPs correlates of EEG relative beta training in ADHD
children. Int J Psychophysiol 2005, 55(1):23–34.
32. Linden M, Habib T, Radojevic V: A controlled study of the effects of EEG
biofeedback on cognition and behavior of children with attention
deficit disorder and learning disabilities. Biofeedback Self Regul 1996,
21(1):35–49.
33. Logemann HN, Lansbergen MM, Van Os TW, Bocker KB, Kenemans JL: The
effectiveness of EEG-feedback on attention, impulsivity and EEG: a sham
feedback controlled study. Neurosci Lett 2010, 479(1):49–53.
34. Duric NS, Elgen I: Norwegian Children and Adolescents with ADHD – A
Retrospective Clinical Study: Subtypes and Comorbid Conditions and
Aspects of Cognitive Performance and Social Skills. Adolescent Psychiatry
2011, 1:349–354.
35. Duric NS, Elgen I: Characteristics of Norwegian children suffering from
ADHD symptoms: ADHD and primary health care. Psychiatry Res 2011,
188(3):402–405.
36. Wechsler D, Corporation P: Wechsler intelligence scale for children. New York:
Psychological Corporation New York; 1949.
37. Wechsler D: Manual for the Wechsler Intelligence Scale for Children. New York:
Psychological Corporation; 1949.
38. Barkley RA: Defiant Children: Second Edition: A Clinician's Manual for
Assessment and Parent Training. Guilford Press 1997.
39. Lubar J: Quantitative Electroencephalographic Analysis (QEEG) Databases
for Neurotherapy:Description,Validation, and Application. New York:
Haworth Medical Press; 2004.
40. Technology T; http://www.thoughttechnology.com.
41. Barkley RA: Defiant Children: Second Edition: A Clinician's Manual for
Assessment and Parent Training. New York: Guilford Press; 1997.
42. Morris SB, DeShon RP: Combining effect size estimates in meta-analysis
with repeated measures and independent-groups designs. Psychol
Methods 2002, 7(1):105–125.
43. Kaiser DA, Othmer O: Effect of Neurofeedback on Variables of Attention
in a Large Multi-Center Trial. J Neurotherapy: Investig Neuromodulation,
Neurofeedback Appl Neuroscience 2000, 4(1):5–15.
Duric et al. BMC Psychiatry 2012, 12:107 Page 8 of 8
http://www.biomedcentral.com/1471-244X/12/10744. Thompson L, Thompson M: Neurofeedback combined with training in
metacognitive strategies: effectiveness in students with ADD. Appl
Psychophysiol Biofeedback 1998, 23(4):243–263.
doi:10.1186/1471-244X-12-107
Cite this article as: Duric et al.: Neurofeedback for the treatment of
children and adolescents with ADHD: a randomized and controlled
clinical trial using parental reports. BMC Psychiatry 2012 12:107.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
